The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.
Disease Severity, Time Managing Symptoms Contribute to High Disease Burden for Patients With AD
A majority of patients with moderate or severe atopic dermatitis (AD) reported moderate-to-high negative impacts on quality of life.
Dupilumab Effective for Pediatric, Adolescent Patients With AD Regardless of Age, Sex, Race
Patients from this diverse cohort experienced improvements in atopic dermatitis (AD) clinical scores after a year or more of treatment with dupilumab.
Study Finds Environmental, Lifestyle Risk Factors of Atopic Dermatitis in Preschool Children
Several environmental and lifestyle factors were associated with significant risk of atopic dermatitis development in preschool children of Shenzhen, China, including the presence of mold in the child’s room, living in a villa/townhouse, and using composite wood floors.
Dr Elaine Siegfried Addresses Patient-Centered Therapeutic Management for Atopic Dermatitis
Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, discusses therapeutic management considerations for dermatologists in consulting with diverse patients with atopic dermatitis.
FDA Widens Use of Dupilumab to Children With AD as Young as 6 Months
The FDA this week expanded the use of dupilumab for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis (AD) whose disease is not controlled with topical prescription therapies or when those treatments can't be used.
Dupilumab Efficacy in Asthma, AD, EoE, and CRSwNP Not Affected By Eosinophil Count
Dupilumab-induced increases in mean eosinophil counts were shown to wane over time in patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and atopic dermatitis (AD), with incidence of eosinophilia not shown to reduce efficacy of the biologic.
Risk of Dementia Elevated in Patients With Atopic Dermatitis
A study of UK electronic health record data indicated patients with atopic dermatitis (AD) showed an increased risk of dementia compared with the general population.
Dr Robert Sidbury Reviews Novel Topical, Systemic Therapies for Pediatric Atopic Dermatitis
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, provides an overview of recent approvals and indications under consideration for the treatment of pediatric atopic dermatitis.
Food Sensitization in Early-Onset AD Linked With Later Allergic Respiratory Diseases
Pediatric patients with early-onset atopic dermatitis (AD) who reported incidence of food sensitization were associated with later allergic respiratory diseases, in which persistence of AD was linked with multiple food allergies.
Greater Atopic Dermatitis Severity May Increase Risk of Certain Cancers
Pediatric and adult patients reporting more severe disease courses of atopic dermatitis had a greater risk of select cancers, particularly lymphoma.
Dr Elaine Siegfried Discusses Skin Color, Socioeconomic Implications of Atopic Dermatitis Management
Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, explains the impact of socioeconomic status on the management of atopic dermatitis in the clinical setting.
Dupilumab Clinically Effective Long Term for Moderate to Severe Pediatric Atopic Dermatitis
Findings of the 52-week phase 3 LIBERTY AD PED-OLE trial showed dupilumab to have an adequate safety profile and incremental clinical benefit with continued use among pediatric patients with moderate to severe atopic dermatitis.
Dr Robert Sidbury Discusses Strategies to Promote Earlier Uptake of Novel Atopic Dermatitis Therapies
Robert Sidbury, MD, MPH, chief, division of dermatology, Seattle Children's Hospital, discussed the emergence of effective therapies for the management of atopic dermatitis and how dermatologists and other providers involved in patient care can better promote earlier use of these treatments.
Study Shows Caregivers Prefer Dermatology Specialists Over PCPs for Pediatric Atopic Dermatitis
Dermatology specialists were cited by diverse caregivers of children with atopic dermatitis (AD) to provide enhanced care delivery and improved AD disease control compared with primary care providers.
Dr Elaine Siegfried on Safety Considerations for JAK Inhibitors in Pediatric Atopic Dermatitis
Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, speaks on safety considerations for the use of Janus kinase (JAK) inhibitors in pediatric patients with atopic dermatitis.
High Disability Burden of Atopic Dermatitis Linked With Socioeconomic Status
Atopic dermatitis was associated with the greatest burden of disease compared with 2 other types of dermatitis, in which high incidence and disability-adjusted life-years rates corresponded with high sociodemographic index areas.
Dr Robert Sidbury on Mental Health Implications of Atopic Dermatitis
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, spoke on the mental health comorbidity risk linked with atopic dermatitis and how dermatologists can play a role in managing behavioral care needs of at-risk patients.
Improved Severity of Atopic Dermatitis Achieved With Adjuvant Dupilumab, Tacrolimus
More patients with atopic dermatitis achieved mild disease severity by 1 month of treatment with adjuvant dupilumab and tacrolimus vs dupilumab alone.
Dr Elaine Siegfried on Considerations for Systemic Therapy Use in Pediatric Atopic Dermatitis
Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, discusses several pediatric patient populations with atopic dermatitis who are candidates for the use of systemic therapies.
Investigating Lifestyle Behaviors Associated With Moderate to Severe Atopic Dermatitis
Several modifiable lifestyle factors were associated with moderate to severe atopic dermatitis in a patient cohort from the Netherlands, including smoking, alcohol consumption, and stress.
Dr Elaine Siegfried Overviews Pathology, Targeted Therapy in Atopic Dermatitis
Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, explains current knowledge on the pathology of atopic dermatitis and use of targeted biologic therapies.
Dupilumab Creates Rapid, Sustained Responses in Asthma, CRSwNP, and AD
Across 3 disease states, dupilumab has been shown to create rapid, clinically meaningful responses that were sustained, which could improve adherence and the patient-provider relationship.
Dr Robert Sidbury Discusses Impact of New AAD Guidelines on Atopic Dermatitis Treatment
Robert Sidbury, MD, MPH, Chief, Division of Dermatology, Seattle Children's Hospital, discussed how new guidelines issued by the American Academy of Dermatology (AAD) regarding comorbidity risk in patients with atopic dermatitis will influence the condition's treatment.
Baricitinib Linked With Improved Skin Pain Severity, Positive QOL in Atopic Dermatitis
Patients with atopic dermatitis who achieved rapid changes in skin pain severity with the Janus kinase inhibitor baricitinib were associated with clinically significant improvement in Dermatology Life Quality Index scores.
Severity of Pediatric Atopic Dermatitis Underestimated by Physicians
Only half of pediatric patients with atopic dermatitis who fit the criteria of having severe disease were identified as such by managing physicians.
Ruxolitinib Cream Improves AD Across Body Regions, Shows Efficacy, Safety in Black Patients
Findings of 2 abstracts presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting showed that ruxolitinib cream (Opzelura) demonstrated significant improvement vs vehicle in patients with atopic dermatitis of Black race and across anatomic regions.
Dr Robert Sidbury Discusses Payer Considerations for Dermatologists Managing Patients With Atopic Dermatitis
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, spoke on considerations for dermatologists in seeking payer coverage of novel, expensive therapies for atopic dermatitis.
House Dust Mite Sublingual Immunotherapy Shows Promise in Atopic Dermatitis
Sublingual immunotherapy with Dermatophagoides pteronyssinus extract was associated with significant improvements in disease severity among patients with atopic dermatitis sensitized to the house dust mite.
Dr Robert Sidbury Addresses Quality-of-Life Burden in Atopic Dermatitis
Along with common symptoms of itch and pain, patients with atopic dermatitis experience significant work productivity and attention issues that affect overall quality of life, said Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital.
Upadacitinib Shows Sustained Efficacy, Safety in Moderate to Severe Atopic Dermatitis
Longer-term findings of the Measure Up 1 and 2 studies showed the JAK inhibitor upadacitinib to be safe and effective after 52 weeks in the treatment of adults and adolescents with moderate to severe atopic dermatitis.
2 Clarke Drive Cranbury, NJ 08512